ADAC sees sharp 1999 net income decline
Nuclear medicine vendor ADAC Laboratories reported mixed results this month when it posted its fiscal 1999 and fourth quarter (end-October) results. After more than a year of financial problems that included restating its revenues for the past three
Nuclear medicine vendor ADAC Laboratories reported mixed results this month when it posted its fiscal 1999 and fourth quarter (end-October) results. After more than a year of financial problems that included restating its revenues for the past three years (SCAN 12/16/98), the Milpitas, CA, company rebounded somewhat to show healthy sales increases for the period, posting revenues of $342.1 million for the year, a 14% climb from 1998s $300.5 million. For the fourth quarter, however, ADACs revenues dipped from $88.8 million in 1998 to $84.8 million.
During fiscal 1999, ADAC reported restructuring charges of $4 million, a research and development charge of $1.4 million, and other non-ordinary charges and expenses of $29.7 million. With the charges, ADAC posted a net loss for the year of $33.6 million; without the charges, the company posted a net loss of $6.6 million. In comparison, ADAC recorded net income of $7.4 million in fiscal 1998. Net income for the fourth quarter was $600,000, compared with net income of $4.1 million in the same period last year.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
